{"entity":{"id":"nct05020769","kind":"trial","name":"SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2/3 trial testing SI-B001 in non-small-cell lung cancer, active and no longer recruiting.","summary":"SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT05020769, led by Sichuan Baili Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer. Planned enrolment is 14 participants (actual). The study started in 2022-01-06 and primary completion is expected in 2025-12. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05020769","url":"https://clinicaltrials.gov/study/NCT05020769"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["si-b001"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05020769","phase":"2/3","setting":"A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical","participation":[{"nct":"NCT05020769","source":"https://clinicaltrials.gov/study/NCT05020769","fetchedAt":"2026-10-07T16:53:32.717Z","studySha256":"fc4fce16adc9d57582672a3dd1a01a7d13b78818e724f699331ecac17a9191e3","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-09-26","leadSponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":14,"enrolmentType":"ACTUAL","siteCount":3,"recruitingSiteCount":0,"countries":["China"]}],"started":"2022-01-06","startedType":"actual","enrolled":14,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05020769/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"si-b001","kind":"drug","name":"SI-B001","route":"/drugs/si-b001/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}